14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CPIX vs IRIX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Cumberland Pharmaceuticals Inc (CPIX) is the stronger overall head-to-head candidate over Iridex Corp (IRIX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CPIX carries a Unified Composite Score of 49.1/100 (HOLD) at $5.21 (50.0x Forward P/E, -4.7% operating margin), whereas IRIX carries 51.8/100 (HOLD) at $0.69 (N/M Forward P/E, -5.4% operating margin).
Composite vs. Pillar Nuance: While IRIX currently prints a higher short-term Unified Composite Score (51.8/100 HOLD vs. CPIX 49.1/100 HOLD), CPIX captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-4.7% vs. -5.4% operating margin) and revenue trajectory (-74.0% vs. -7.4% YoY).
Technical & Structure Timing Caution: CPIX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.1); meanwhile IRIX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Medical Devices value chain with $12.1M market capitalization and -5.4% operating margin.
OpEx & R&D Reinvestment41.3% of Rev ($21M)
90D Engineering Disclosures0 Published
Investor FAQ CPIX vs IRIX Key Questions & Quantitative Answers
As of Nov 16, 2026, Cumberland Pharmaceuticals Inc (CPIX) is the stronger overall head-to-head candidate over Iridex Corp (IRIX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CPIX carries a Unified Composite Score of 49.1/100 (HOLD) at $5.21 (50.0x Forward P/E, -4.7% operating margin), whereas IRIX carries 51.8/100 (HOLD) at $0.69 (N/M Forward P/E, -5.4% operating margin). Composite vs. Pillar Nuance: While IRIX currently prints a higher short-term Unified Composite Score (51.8/100 HOLD vs. CPIX 49.1/100 HOLD), CPIX captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-4.7% vs. -5.4% operating margin) and revenue trajectory (-74.0% vs. -7.4% YoY). Technical & Structure Timing Caution: CPIX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.1); meanwhile IRIX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IRIX leads the Growth & Scale pillar: CPIX posts -74.0% YoY revenue growth and +0.0% YoY earnings growth on $46M TTM revenue (83.3% gross margin, -4.7% operating margin), compared with IRIX at -7.4% YoY revenue growth and +0.0% YoY earnings growth on $52M TTM revenue (35.9% gross margin, -5.4% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), CPIX cumulative revenue shifted +33.3% while IRIX shifted +25.0%. In operating R&D and SG&A reinvestment, CPIX deploys N/A (0 90-day corporate R&D disclosures) versus 41.3% of Rev ($21M) (0 disclosures) for IRIX.
CPIX screens cheaper on headline valuation multiples. CPIX trades at 50.0x Forward P/E, 50.0x Trailing P/E, 1.67x PEG, and 1.9x EV/Revenue (4.3% EBITDA margin), whereas IRIX trades at N/M Forward P/E, N/M Trailing P/E, 0.94x PEG, and 0.2x EV/Revenue (-4.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CPIX (-3.4% ROE) versus IRIX (-73.2% ROE) capital efficiency.
In options market volatility and institutional positioning, CPIX carries 296.2% implied volatility (37th %ile, Balanced (25th–60th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.44β · 222% Vol realized risk). By comparison, IRIX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.66β · 58% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.